employee
International Society "Stress under Control" (Vice-President)
employee
employee
student
employee
State Autonomous Healthcare Institution of the Tyumen Region "Regional Treatment and Rehabilitation Center" (Chief Physician)
employee
Tyumen, Russian Federation
VAK Russia 3.1.24
CSCSTI 76.29
Many patients at the polyclinic complain of symptoms that cannot be explained by the presence and/or exacerbation of any somatic disease. For example, “cardialgia of non-cardiac origin” is widespread. In foreign literature, such conditions are referred to as “symptoms that are medically unexplained”; in our country, another definition is adopted – vegetative dystonia syndrome. Such patients often undergo expensive examinations, undergo consultations with various specialists, and receive ineffective treatment, which, as a rule, does not lead to a positive result, causing dissatisfaction among both patients and doctors. The optimal treatment strategy includes individually selected psychotherapy in combination with medicinal and non-medicinal methods of treatment and prevention. Therapy of clinically expressed anxiety by a non-psychiatrist is possible with the use of psychotropic drugs. The article discusses anxiolytics of various mechanisms of action, including the atypical benzodiazepine tranquilizer tophizopam, which has a number of advantages over other tranquilizers: lack of sedation, muscle relaxation and cognitive impairment, effectiveness in somatovegetative symptoms of anxiety, safety for daily use, and the presence of a mild stimulating effect.
medically unexplained symptoms, vegetative dystonia syndrome, psychosomatic disorders, psychological stability, social support, psychopharmacotherapy, tranquilizers, tophizopam
1. Trevoga u somaticheskogo pacienta: mif ili real'nost'? / E. S. Akarachkova, E. V. Dovgan', L. R. Kadyrova [i dr.] // RMZh. – 2024. – № 5. – S. 2-6. – EDN GRFKGV.
2. Frese T., Mahlmeister J., Heitzer M, Sandholzer H. Chest pain in general practice: frequency, management, and results of encounter // J Family Med Prim Care. 2016. Vol. 5. P. 61.
3. Primenenie Mebiksa v psihiatrii i obschey medicine: aktual'nost', perspektivy, klinicheskie primery / O. V. Kotova, V. E. Medvedev, E. S. Akarachkova, A. A. Belyaev // Klinicheskiy razbor v obschey medicine. – 2024. – T. 5, № 8. – S. 56-61. – DOIhttps://doi.org/10.47407/kr2024.5.8.00460.
4. Ebell M.H. Evaluation of chest pain in primary care patients // Am Fam Physician. 2011. Vol. 83. P. 603–605.
5. Mayou R, Kirmayer LJ, Simon G, Kroenke K, Sharpe M. Somatoform disorders: time for a new approach in DSM-V. Am J Psychiatry. (2005) 162:847–55.https://doi.org/10.1176/appi.ajp.162.5.847.
6. Na prieme - trevozhnyy pacient / E. S. Akarachkova, L. R. Kadyrova, L. V. Klimov [i dr.] // Consilium Medicum. – 2024. – T. 26, № 2. – S. 125-130. – DOIhttps://doi.org/10.26442/20751753.2024.2.202672.
7. Slavney PR, Teitelbaum ML. Patients with medically unexplained symptoms: DSM- III diagnoses and demographic characteristics. Gen Hosp Psychiatry. (1985)7:21–5.https://doi.org/10.1016/0163-8343(85)90006-4.
8. Sindrom vegetativnoy disfunkcii: diagnostika i lechenie / O. V. Kotova, A. A. Belyaev, E. S. Akarachkova [i dr.] // Terapiya. – 2023. – T. 9, № 9(71). – S. 168-175. – DOIhttps://doi.org/10.18565/therapy.2023.9.168-175. – EDN ZFGKYZ.
9. The The Federation of Mental Health in General Hospital Chinese Psychiatrist Association The The Chinese Expert Consensus on Clinical Practice of “Medically Unexplained Symptoms” Group. The Chinese expert consensus on clinical practice of “medically unexplained symptoms”. Chin J Intern Med. (2017) 56:150–6.https://doi.org/10.3760/cma.j.issn.0578-1426.2017.02.017.
10. Roenneberg C, Sattel H, Schaefert R, Henningsen P, Hausteiner-Wiehle C. Functional somatic symptoms. Dtsch Arztebl Int. (2019) 116:553–60.https://doi.org/10.3238/arztebl.2019.0553.
11. Dimsdale JE, Creed F, Escobar J, Sharpe M, Wulsin L, Barsky A, et al. Somatic symptom disorder: an important change in DSM. J Psychosom Res. (2013) 75:223–8
12. WHO's new International Classification of Diseases (ICD-11) Comes Into Effect . World Health Organization. (2022). Available online at: https://icd.who.int/browse11/I-m/en (accessed June 15, 2022).
13. Sharpe M, Mayou R, Walker J. Bodily symptoms: new approaches to classification. J Psychosom Res. (2006) 60:353–6.https://doi.org/10.1016/j.jpsychores.2006.01.020.
14. ShuQiao Y, YanJie Y. Medical Psychology. Beijing, China: People's Medical Publishing House in Chinese. (2018). p. 118.
15. Zhang J, Pan Y, Hong J, Guo H, Wang M, Liu X, Dong Y, Wang D, Liu L, Tan S, Jiang R. Differences of medically unexplained symptoms among patients of different ages and sexes in the psychological clinic of a general hospital and the influencing factors of MUS: A cross-sectional study. Front Psychiatry. 2022 Aug 4;13:930212. doi:https://doi.org/10.3389/fpsyt.2022.930212.
16. Allen LA, Gara MA, Escobar JI, Waitzkin H, Silver RC. Somatization: a debilitating syndrome in primary care. Psychosomatics. (2001) 42:63–7.https://doi.org/10.1176/appi.psy.42.1.63.
17. Murakami M, Nakai Y. Current state and future prospects for psychosomatic medicine in Japan. Biopsychosoc Med. (2017) 11:1.https://doi.org/10.1186/s13030-017-0088-6.
18. Stress i rasstroystva, svyazannye s nim / O. V. Kotova, V. V. Zaharov, E. S. Akarachkova [i dr.] // Povedencheskaya nevrologiya. – 2024. – № 1. – S. 30-36. – DOIhttps://doi.org/10.46393/27129675_2024_1_30.
19. Seligman ME, Csikszentmihalyi M. Positive psychology. An introduction. Am Psychol. (2000)55:5–14.https://doi.org/10.1037/0003-066X.55.1.5.
20. Nazari S, Afshar PF, Sadeghmoghadam L, Shabestari AN, Farhadi A. Developing the perceived social support scale for older adults: a mixed-method study. AIMS Public Health. (2020) 7:66–80.https://doi.org/10.3934/publichealth.2020007.
21. Gureje O, Simon GE, Ustun TB, Goldberg DP. Somatization in cross-cultural perspective: a World Health Organization study in primary care. Am J Psychiatry. (1997) 154:989–95.https://doi.org/10.1176/ajp.154.7.989.
22. Ballering AV, Bonvanie IJ, Olde Hartman TC, Monden R, Rosmalen J. Gender and sex independently associate with common somatic symptoms and lifetime prevalence of chronic disease. Soc Sci Med. (2020) 253:112968.https://doi.org/10.1016/j.socscimed.2020.112968.
23. Stress: prichiny i posledstviya, lechenie i profilaktika. Klinicheskie rekomendacii / Akarachkova E.S., Baydauletova A.I., Belyaev A.A., Blinov D.V, Gromova O.A., Dulaeva M.S., Zamergrad M.V, Isaykin A.I., Kadyrova L.R., Klimenko A.A., Kondrashov A.A., Kosivcova O.V., Kotova O.V., Lebedeva D.I., Medvedev V.E., Orlova A.S., Travnikova E.V., Yakovlev O.N. — SPb.: Skifiya-print; M.: Profmedpress, 2020. — 138 s. ISBN 978-5-98620-480-2.
24. Akarachkova E.S., Klimov L.V., Kotova O.V.. 21 vek: ot pandemii COVID-19 k novym psihosocial'nym stressam. Klinicheskoe rukovodstvo. [Elektronnyy resurs]. – M.: Izdatel'stvo «Pero», 2022. ISBN 978-5-00204-108-4
25. Kotova, O. V. Sovremennye metody diagnostiki i lecheniya trevozhnyh i depressivnyh rasstroystv / O. V. Kotova, A. A. Belyaev, E. S. Akarachkova // RMZh. Medicinskoe obozrenie. – 2021. – T. 5, № 10. – S. 648-653. – DOIhttps://doi.org/10.32364/2587-6821-2021-5-10-648-653. – EDN CQIXKM.
26. Kotova, O. V. Sochetanie serdechno-sosudistyh zabolevaniy i trevogi/depressii u pozhilyh pacientov: kak povysit' effektivnost' lecheniya i kachestvo zhizni / O. V. Kotova, E. S. Akarachkova // RMZh. – 2018. – T. 26, № 1-2. – S. 95-99. – EDN THQYDP.
27. Artemenko A.R., Oknin V.Yu. Grandaksin v lechenii psihovegetativnyh rasstroystv // Lechenie nervnyh bolezney. 2001. T.2. №1. S.24–27 [Artemenko A.R., Oknin V.Yu. Grandaksin v lechenii psihovegetativnyh rasstrojstv // Lechenie nervnyh boleznej. 2001. T.2. №1. S.24–27 (in Russian)].
28. Veyn A.M., Dyukova G.M. Vorob'eva O.V., Danilov A.B. Panicheskie ataki (nevrologicheskie i psihofiziologicheskie aspekty). SPb., 1997. 304 s. [Vejn A.M., Dyukova G.M. Vorob’eva O.V., Danilov A.B. Panicheskie ataki (nevrologicheskie i psihofiziologicheskie aspekty). SPb., 1997. 304 s. (in Russian)].
29. Mangot A and Murthy V. Psychiatric aspects of phosphodiesterases: an overview. Indian J Pharmacol, 2015; 47: 594
30. Üçel UI, Can ÖD, Özkay ÜD, et al. Antiamnesic effects of tofisopam against scopolamine-induced cognitive impairments in rats. Pharmacol Biochem Behav, 2020; 190: 172858.
31. Cashman JR, Voelker T, Zhang H-T, et al. Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. J Med Chem, 2009; 52 1530–1539.
32. Srivastava S, Bhatia MS, Gupta K, and Rajdev K. Current update on evidence-based literature of tofisopam. Delhi Psychiatry J, 2014; 17 154–159.
